Write in a clean editor, then format for Open Forum Infectious Diseases in one click — DocuGuru applies the official Oxford University Press template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Open Forum Infectious Diseases is a peer-reviewed journal published by Oxford University Press, covering Antibiotic Use and Resistance, Bacterial Identification and Susceptibility Testing, Respiratory viral infections research.
| Publisher | Oxford University Press |
|---|---|
| Reference style | Author–year (OUP) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Open Forum Infectious Diseases, 12(3), pp. 45–58.
Formats any DOI in the closest standard style — Open Forum Infectious Diseases has no published style definition, so this is an approximation. No sign-up. |
| Publishes research in | Antibiotic Use and Resistance Bacterial Identification and Susceptibility Testing Respiratory viral infections research Antibiotic Resistance in Bacteria Antimicrobial Resistance in Staphylococcus |
| ISSN | 2328-8957 |
| Citation impact (2-yr) | 0.99 |
| h-index | 101 |
| i10-index | 3,063 |
| Total citations | 119,462 |
| Article processing charge | $3,064 |
| Open access | Yes |
| Top institutions publishing here | Centers for Disease Control and Prevention |
| Journal website | academic.oup.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Abstract Background The emergence of antifungal resistance threatens effective treatment of invasive fungal infection (IFI). Invasive candidiasis is the most common health care–associated IFI. We evaluated the activity of fluconazole (FLU) against 20 788 invasive isolates of Candida (37 species) collected from 135 medical centers in 39 countries (1997–2016). The activity of anidulafungin, caspofungin, and…
Abstract Background There is a need to better define the epidemiology of sepsis in intensive care units (ICUs) around the globe. Methods The Intensive Care over Nations (ICON) audit prospectively collected data on all adult (>16 years) patients admitted to the ICU between May 8 and May 18, 2012, except those admitted for less than…
This article provides a comprehensive review of currently available treatment options for infections due to carbapenem-resistant Enterobacteriaceae (CRE). Antimicrobial resistance in Gram-negative bacteria is an emerging and serious global public health threat. Carbapenems have been used as the "last-line" treatment for infections caused by resistant Enterobacteriaceae, including those producing extended spectrum ß-lactamases. However, Enterobacteriaceae that…
The outbreak of coronavirus disease 2019 (COVID-19) has spread rapidly in China. Until now, no definite effective treatment has been identified. We reported on 3 patients with severe COVID-19 who received high-dose intravenous immunoglobulin (IVIg) with satisfactory recovery. Based on these observations, randomized studies of high-dose IVIg should be considered in deteriorating patients infected with…
is a leading cause of diarrhea globally. Largely an infection of impoverished communities in developing countries, amebiasis has emerged as an important infection among returning travelers, immigrants, and men who have sex with men residing in developed countries. Severe cases can be associated with high case fatality. Polymerase chain reaction-based diagnosis is increasingly available but…
